Zepbound day-one videos: what TikTok gets right and wrong

What did @wrenchboss_nj actually say?

On day one of his Zepbound prescription, @wrenchboss_nj laid out his understanding of the drug for 56,000-plus viewers. He said Zepbound "is used to treat sleep apnea and weight loss," called it "kind of like Ozempic, but not really the same," and argued the key difference is that Ozempic is for "type two diabetes and cardiovascular disease" while Zepbound targets sleep apnea and weight. He also claimed Zepbound "is more proven to lose weight compared to Ozempic." He paid $372 with insurance, noted the list price would have been roughly $1,300, and was transparent that he's currently losing weight on his own and taking Adderall. Credit where it's due: that level of disclosure is genuinely rare on weight-loss TikTok.

Does the science back this up?

Partially, but the framing has real problems. Tirzepatide (Zepbound) and semaglutide (Ozempic/Wegovy) are not just different brands of the same mechanism. That distinction matters clinically, and the weight-loss comparison is more complicated than "more proven."

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist only. In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), tirzepatide at the highest dose produced mean weight loss of about 20.9% of body weight over 72 weeks in adults with obesity. In the STEP 1 trial (Wilding et al., 2021, NEJM), semaglutide 2.4mg produced about 14.9% mean weight loss. So tirzepatide does show larger average weight loss in trials, though these are different study populations and not head-to-head comparisons. Calling it "more proven" oversimplifies a legitimate but nuanced finding.

On sleep apnea: the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in June 2024, based on the SURMOUNT-OSA trial (Malhotra et al., 2024, NEJM). That is a real, recent, and specific approval. He got that right.

What did they get wrong (or right)?

The Ozempic framing is where things slip. Saying Ozempic is used "for type two diabetes and cardiovascular disease" while Zepbound is for "sleep apnea and weight loss" sets up a false either/or. Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction, yes. But semaglutide at 2.4mg (branded Wegovy) is also FDA-approved for chronic weight management. Conflating Ozempic and Wegovy, which happens constantly on social media, misleads people about what's actually available for weight loss.

He also says tirzepatide has "different ingredients" than Ozempic, which is technically true but vague in a way that might imply they're completely unrelated drug classes. They share a GLP-1 mechanism. The difference is tirzepatide adds GIP agonism, which is meaningfully distinct but not a total departure.

What he got right: the sleep apnea indication is accurate. The price transparency is valuable. And his acknowledgment that he's "losing weight on my own right now" suggests he's not treating this as a magic fix, which is the right frame for any GLP-1 therapy.

What should you actually know?

If you're considering Zepbound or any GLP-1 therapy after watching videos like this, a few things are worth understanding before you talk to a provider.

• Tirzepatide (Zepbound/Mounjaro) and semaglutide (Ozempic/Wegovy) are related but mechanistically different drugs. Your eligibility, insurance coverage, and likely response may differ based on your specific health profile.
• The sleep apnea approval for Zepbound is specifically for adults with obesity, not a standalone sleep apnea treatment. Weight loss is the mechanism, not a direct action on airway anatomy.
• The weight-loss comparison between tirzepatide and semaglutide is promising but not settled. No large randomized head-to-head trial comparing them directly for weight loss has been published as of early 2025.
• $372 with insurance and roughly $1,300 without reflects a real access problem for this drug class. Manufacturer savings cards can reduce out-of-pocket costs, but eligibility varies and these programs have income and insurance restrictions.
• Combining GLP-1 medications with stimulants like Adderall is something that requires explicit provider oversight. Both can suppress appetite and affect cardiovascular function. This is not a stack to manage informally.